By interrupting the adenoma-carcinoma sequence, endo-scopic polypectomy can prevent the development of colorectal cancer (CRC). Endoscopic polypectomy has, therefore, become an accepted screening and surveillance modality for CRC and has been widely adopted by clinicians, policymakers, and professional organizations as an effective screening tool. Most gastroenterologists are adequately trained to endoscopically excise the majority of polyps found in a routine colonoscopy. However, some polyps, due to their size, location, or configuration, are considered more technically challenging or are associated with an increased risk of complications (such as bleeding or perforation) and, hence, are not routinely resected. These so-called complex polypectomies are the focus of this paper.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920588 | PMC |
Publication Analysis
Top Keywords
Similar Publications
KB-0118, A novel BET bromodomain inhibitor, suppresses Th17-mediated inflammation in inflammatory bowel disease.
Biomed Pharmacother
March 2025
Department of Microbiology and Immunology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul 03722, Republic of Korea; Pohang University of Science and Technology, Pohang 37673, Republic of Korea. Electronic address:
Inflammatory bowel disease (IBD) presents complex pathologies and remains challenging to treat, highlighting the urgent need for innovative therapeutics. This study evaluates KB-0118, a novel BET bromodomain inhibitor targeting BRD4, for its immunomodulatory effects in IBD. KB-0118 effectively inhibited pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a, and selectively suppressed Th17 cell differentiation, a critical driver of IBD pathology.
View Article and Find Full Text PDFPredictive accuracy of the complex 30-day model for colon surgical site infections in emergent operations.
Am J Surg
March 2025
Division of Surgical Oncology, Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, NC, USA. Electronic address:
Background: Surgical site infections (SSI) following colon surgery continue to pose a significant clinical and financial impact on a healthcare system. The National Healthcare Safety Network (NHSN) utilizes the Complex 30-day SSI model to report the predictive number of infections for a hospital, which is submitted to the Centers for Medicare and Medicaid Services. However, this model does not account for patient acuity.
View Article and Find Full Text PDFLow-Grade Cystic Mucinous Neoplasm of the Colon: A New Entity? Case Report and Review of Literature.
J Gastrointest Cancer
March 2025
Houston Colon PLLC, Houston, TX, USA.
Low-grade cystic mucinous neoplasm of the sigmoid colon has never been previously reported and a classification for such a tumor does not currently exist. Here, we present a case of low-grade cystic mucinous neoplasm of the sigmoid colon and discuss the differential diagnosis especially as it relates to clinical management. Our case is a 68-year-old male who presented with anemia and a history of a lower gastrointestinal tract bleed.
View Article and Find Full Text PDFProtein arginine methyltransferase 6 enhances immune checkpoint blockade efficacy via the STING pathway in MMR-proficient colorectal cancer.
J Immunother Cancer
March 2025
Laboratory of Targeted Therapy and Precision Medicine, Department of Clinical Laboratory, Shanghai 6th Peoples Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
Background: The emergence of immunotherapy has revolutionized the paradigm of cancer treatment with immune checkpoint blockades (ICB) in solid cancers, including colorectal cancer (CRC). However, only a small subset of CRC patients harboring deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) benefits from ICB therapy. A very limited response to ICB therapy has been achieved in MMR-proficient CRC, representing a significant challenge limiting the clinical application of immunotherapy.
View Article and Find Full Text PDFTemporal trends in incidence and mortality of colorectal cancer in Denmark from 2007 to 2022.
Int J Cancer
March 2025
Department of Surgery, HPB Section, Aarhus University Hospital, Aarhus, Denmark.
Colorectal cancer (CRC) is the third most common cancer in the Western world and represents a significant burden on healthcare systems worldwide. We aimed to describe temporal trends in incidence, tumor characteristics, and survival for patients with CRC in a nationwide, population-based cohort in Denmark. We used population-based Danish healthcare registries to study all patients diagnosed with CRC from 2007 to 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!